Lexicon Presents Sotagliflozin Heart Benefits Nov 2025

The Woodlands, TX – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is poised to unveil significant new data on its innovative heart failure drug, sotagliflozin (brand name INPEFA®), at two leading cardiology conferences scheduled for November 2025 in New Orleans, Louisiana. These presentations are anticipated to highlight the drug’s unique benefits across diverse patient populations, including a novel look at its effects in individuals with hypertrophic cardiomyopathy (HCM).

The first presentation will take place at the Hypertrophic Cardiomyopathy Society (HCMA) 2025 Annual Scientific Sessions, running from November 1-2, 2025. A new analysis derived from the pivotal Phase 3 SOLOIST-WHF trial will delve into sotagliflozin’s impact on heart failure-related outcomes specifically for patients diagnosed with hypertrophic cardiomyopathy. HCM is a genetic condition characterized by the abnormal thickening of the heart muscle, affecting approximately 1 in 500 individuals and often leading to severe symptoms and an increased risk of sudden cardiac death. Current treatments primarily manage symptoms, making the potential for a targeted therapeutic approach in this area highly significant for the medical community and patients alike. More information on the society can be found at www.4hcm.org.

Following this, the American Heart Association (AHA) Scientific Sessions 2025, from November 8-11, 2025, will host additional detailed analyses of sotagliflozin. These presentations will further explore the drug’s impact on crucial outcomes such as cardiovascular death and heart failure events. One analysis will categorize these findings for patients with type 2 diabetes and recent worsening heart failure based on their baseline Body Mass Index (BMI), offering valuable insights into the drug’s efficacy across different weight profiles. Another presentation will investigate the timing and magnitude of sotagliflozin’s benefits on similar outcomes for patients with type 2 diabetes and heart failure, stratified by their estimated Glomerular Filtration Rate (eGFR), which indicates kidney function. This analysis will help clinicians understand how quickly and substantially patients can expect to benefit, and its effectiveness in patients with varying degrees of kidney health. Details about the AHA Scientific Sessions are available at professional.heart.org/en/meetings/scientific-sessions.

Sotagliflozin, marketed as INPEFA®, is a first-in-class dual SGLT1 and SGLT2 inhibitor. Unlike other SGLT2 inhibitors that primarily block glucose reabsorption in the kidneys, sotagliflozin’s dual mechanism also targets SGLT1, blocking glucose absorption in the gastrointestinal tract. This unique action is believed to contribute to its broad cardiovascular benefits. The drug received FDA approval in May 2023 for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

The SOLOIST-WHF trial was instrumental in securing sotagliflozin’s approval, demonstrating a significant reduction in heart failure events and cardiovascular death in patients with type 2 diabetes and recent worsening heart failure. These upcoming analyses aim to refine the understanding of its benefits in specific, high-need patient subgroups. Analyzing data by BMI and eGFR is critical, as heart failure often coexists with obesity and chronic kidney disease, allowing clinicians to better tailor treatment plans and predict outcomes for a diverse range of patients.

“We are incredibly excited to share these comprehensive new analyses of sotagliflozin at two of the most important cardiology meetings next year,” said Dr. Lonnel Coats, Chief Executive Officer of Lexicon Pharmaceuticals. “The data on hypertrophic cardiomyopathy patients represent a crucial step forward in understanding the potential breadth of INPEFA’s impact. Furthermore, a deeper dive into how our drug benefits patients across different BMI and kidney function levels, and the speed of those benefits, will provide clinicians with vital information to optimize treatment for those suffering from heart failure.”

**About Lexicon Pharmaceuticals**
Lexicon is a biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough treatments for serious diseases. The company’s lead product, INPEFA® (sotagliflozin), is approved by the FDA for the reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Lexicon is headquartered in The Woodlands, Texas. For more information, please visit www.lexiconpharmaceuticals.com.

**Forward-Looking Statements**
This news story contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, among others, statements relating to the clinical development and therapeutic and commercial potential of sotagliflozin. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other factors, many of which are beyond Lexicon’s ability to control, that may cause Lexicon’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include those discussed in Lexicon’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained herein speak only as of the date hereof, and Lexicon undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the date hereof.